Article

BREAKING: Deal Near on SGR Fix

The joint House-Senate conference committee tasked with fixing the Medicare SGR formula is nearing a deal, according to news sources.

The $20-billion fix, which would avoid a 28% cut in physician payments scheduled to begin March 1, would reportedly be offset by cuts in the budget.

Source: MedPage Today

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
5 experts are featured in this series
2 experts in this video
5 experts are featured in this series
4 experts are featured in this series.
Related Content
Image Credit: Dusan Petkovic - stock.adobe.com
July 11th 2025

Drinking Water Contaminants Linked to Higher Chronic Kidney Disease Risk

Giuliana Grossi
Long-term exposure to water contaminants, even below the regulatory limits, significantly increases the risk of chronic kidney disease.
Managed Care Cast
July 8th 2025

Managed Care Cast News Roundup: July 8, 2025

Giuliana Grossi
Medical societies challenge HHS Secretary Robert F. Kennedy Jr's COVID-19 vaccine rollbacks, and more news updates from the week.
IV chemotherapy-Aidman-stock.adobe.com
July 11th 2025

Patients With Advanced NSCLC Face Critical Treatment Gaps

Giuliana Grossi
New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for innovative therapies to improve patient outcomes.
Managed Care Cast
July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bobb, MPH

Giuliana Grossi Anna Bobb, MPH
Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bobb, MPH, executive director of the Path Forward coalition.
In the Press
July 11th 2025

AJMC® in the Press, July 11, 2025

Julia Bonavitacola
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
The primary outcome measure in the ambulatory cohort in the study was mean change from baseline to week 52 in the TTR from floor, and no significant differences were seen between the treatment and control groups. | Image credit: OlegKachura - stock.adobe.com
July 11th 2025

TAS-205 Misses Primary End Point in Phase 3 DMD Trial

Rose McNulty
TAS-205 showed no significant impact on motor function in patients with Duchenne muscular dystrophy (DMD), highlighting the ongoing search for effective treatments for the rare condition.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo